礼来VS诺和诺德,互撕!

药联视界
Jan 17

摩根大通医疗健康大会(JPM)现场近日上演激烈交锋,诺和诺德新任CEO Mike Doustdar公开抨击礼来在研口服GLP-1受体激动剂奥氟格列隆(Orforglipron)的临床方案“糟糕透顶”。数小时后,礼来CEO Dave Ricks以嘲讽语气回应,称对手对自家临床方案的细致研读“令人印象深刻”,并强调药物相互作用研究尚未完成,暗指质疑为时过早。这场高层隔空互撕,正是全球GLP-1口服减重...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10